Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 171 participants.

Also called NCT07093476

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 171 participants (planned count) (from the registry)
Sponsor
  • Celltrion Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07093476
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07093476. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-18 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
Condition
T2DM
Condition
Diabete Type 2
Condition
DM
Intervention (Drug)
Metformin
Intervention (Drug)
Alogliptin
Intervention (Drug)
empagliflozin
Lead sponsor
Celltrion (class: industry)

Record details

Record id
cardio:ct-nct07093476
Content hash
56b80a42fccf7e33e63a8ef82e8ce288dc53512dc713ade6bb33c1b4ac5d271b